Real-World Effectiveness of Tafamidis 80 mg or 61 mg on Neurologic Disease Progression in Patients With Mixed-Phenotype Hereditary Transthyretin Amyloid Cardiomyopathy
Latest Information Update: 14 Aug 2023
At a glance
- Drugs Tafamidis meglumine (Primary)
- Indications Transthyretin-related hereditary amyloidosis
- Focus Therapeutic Use
- Sponsors Pfizer
- 19 Jul 2023 Status changed from active, no longer recruiting to completed.
- 19 Apr 2023 Planned End Date changed from 1 Mar 2023 to 1 Nov 2023.
- 19 Apr 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Nov 2023.